# A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Source: https://onco.cc/trials/nct06973187/  
OnCo record `nct06973187` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pirtobrutinib in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.

## Summary

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is a phase 3 interventional study registered as NCT06973187 by BeOne Medicines, with 500 participants planned, started 2025-09-04 and due to reach its primary completion in 2028-04-17. Interventions recorded: Tacabrutideg and Pirtobrutinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06973187
- Phase: 3
- Setting: A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Sponsor: BeOne Medicines
- Enrolled: 500

## Sources

- ClinicalTrials.gov NCT06973187: https://clinicaltrials.gov/study/NCT06973187

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Pirtobrutinib](https://onco.cc/drugs/pirtobrutinib/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct06973187.json